Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions

• Verfasst von: Gwenzi, Tafirenyika [VerfasserIn]
• Verfasst von: Zhu, Anna [VerfasserIn]
• Verfasst von: Schrotz-King, Petra [VerfasserIn]
• Verfasst von: Schöttker, Ben [VerfasserIn]
• Verfasst von: Hoffmeister, Michael [VerfasserIn]
• Verfasst von: Brenner, Hermann [VerfasserIn]
• Titel: Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions
• Titelzusatz: systematic review and meta-analysis of randomized trials
• Verf.angabe: Tafirenyika Gwenzi, Anna Zhu, Petra Schrotz-King, Ben Schöttker, Michael Hoffmeister, Hermann Brenner
• E-Jahr: 2023
• Jahr: July 2023
• Umfang: 9 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 17. Mai 2023, Artikelversion: 14. Juni 2023 ; Gesehen am 01.08.2023
• Titel Quelle: Enthalten in: Clinical nutrition
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1982
• Jahr Quelle: 2023
• Band/Heft Quelle: 42(2023), 7 vom: Juli, Seite 1142-1150
• ISSN Quelle: 1532-1983
• DOI: doi:10.1016/j.clnu.2023.05.009
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarker
• Sach-SW: Cancer
• Sach-SW: Inflammation
• Sach-SW: Precancer
• Sach-SW: Vitamin D3 supplement
• K10plus-PPN: 1854050184

Abstract

Background & aims - Inflammation plays a key role in tumor development and progression. Vitamin D has potential tumor suppressing effects through modulation of inflammatory processes. The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to summarize and evaluate the effects of vitamin D3 supplementation (VID3S) on serum inflammatory biomarkers among patients with cancer or pre-cancerous lesions. - Methods - We searched PubMed, Web of Science and Cochrane databases until November 2022. The effects of VID3S were estimated from pooled standardized mean differences (SMDs) with their 95% confidence intervals (CIs) for inflammatory biomarker follow-up levels between intervention and control groups. - Results - Meta-analysis of eight RCTs (total of 592 patients with cancer or pre-cancerous conditions) showed that VID3S significantly lowered levels of serum tumor necrosis factor (TNF)-α (SMD [95%CI]: −1.65 [−3.07; −0.24]). VID3S also resulted in statistically non-significantly lower serum levels of interleukin (IL)-6 (SMD [95%CI]: −0.83, [−1.78; 0.13]) and C-reactive protein (CRP) (SMD [95%CI]: −0.09, [−0.35; 0.16]), whereas IL-10 levels were unaltered (SMD [95%CI]: −0.00, [−0.50; 0.49]). - Conclusion - Our study shows evidence of a significant reduction of TNF-α levels by VID3S for patients with cancer or precancerous lesions. Patients with cancer or precancerous lesions may benefit from personalized VID3S in suppressing tumour-promoting inflammatory response. - Prospero registration number - CRD42022295694.